Trials / Completed
CompletedNCT00163618
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 7 Years – 11 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to assess the TBE antibody persistence approximately three years after administration of a TBE booster vaccination with FSME-IMMUN 0.25 ml Junior in children who received either 0.25 mL or 0.5 mL TicoVac for their primary vaccination series in Study 146A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl |
Timeline
- Start date
- 2005-06-01
- Completion
- 2006-07-01
- First posted
- 2005-09-14
- Last updated
- 2015-05-21
Locations
4 sites across 1 country: Austria
Source: ClinicalTrials.gov record NCT00163618. Inclusion in this directory is not an endorsement.